证券代码：301087 证券简称：可孚医疗 公告编号：2026-001 可孚医疗科技股份有限公司 第二届董事会第二十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 鉴于公司第二届董事会任期即将届满，根据《公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等法律法规、规范性文件及《公司章程》的有关规定，公司 拟按照相关法律程序进行董事会换届选举。董事会同意提名张敏先生、张志明先 生、薛小桥先生为公司第三届董事会非独立董事候选人。第三届董事会非独立董 事任期自公司 2026 年第一次临时股东会通过之日起三年。该议案采用逐项表决 方式，具体表决结果如下： 1.01 提名张敏先生为公司第三届董事会非独立董事候选人 表决结果：同意 7 票，反对 0 票，弃权 0 票。 1 1.02 提名张志明先生为公司第三届董事会非独立董事候选人 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第二十次会 议于 2025 年 12 月 27 日以电子邮件的方式发出会议通知， ...

可孚医疗科技股份有限公司 董事、高级管理人员薪酬管理制度 第一章 总则 第一条 为规范可孚医疗科技股份有限公司(以下简称"公司")董事、高 级管理人员的薪酬管理，建立科学有效的激励与约束机制，有效调动公司董事、 高级管理人员的工作积极性，提高公司的经营管理效益，根据《中华人民共和 国公司法》《中华人民共和国证券法》《上市公司章程指引》《上市公司治理 准则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规 范运作》等有关法律法规、规范性文件及《公司章程》的有关规定，结合公司 实际情况，特制定本制度。 第二条 本制度适用于《公司章程》规定的董事和高级管理人员。 第三条 公司薪酬制度遵循以下原则： (一) 公平原则，体现收入水平符合公司规模与业绩的原则，同时与外部 薪酬水平相符： (二) 责、权、利统一原则，体现薪酬与岗位价值高低、履行责任义务大 小相符； (三) 长远发展原则，体现薪酬与公司持续健康发展的目标相符； (四) 激励约束并重原则，体现薪酬发放与考核、奖惩、激励机制挂钩。 第二章 薪酬管理机构 第四条 公司董事会负责审议公司高级管理人员的薪酬，公司股东会负责 审议董事的薪酬。 第五条 ...

（1）现场会议时间：2026年1月16日（星期五）15:00 证券代码：301087 证券简称：可孚医疗 公告编号：2026-003 可孚医疗科技股份有限公司 关于召开 2026 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 4、会议时间： （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026年1月16日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2026年1月16日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026年1月13日（星期二） 7、出席对象： （1 ...

每经AI快讯，可孚医疗12月31日晚间发布公告称，公司第二届第二十次董事会会议于2025年12月31日 在公司六楼会议室召开。会议审议了《关于召开2026年第一次临时股东会的议案》等文件。 每日经济新闻 （记者 曾健辉） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经头条（nbdtoutiao）——2025十大财经新闻出炉！护航、酣战、变局、狂飙分别指向哪些大事件？ ...

Group 1 - The core viewpoint of the article highlights the performance and financial metrics of Kefu Medical (301087) as of December 29, 2025, showing a slight decline in stock price and mixed capital flow [1][2] - Kefu Medical reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 6.63% [2] - The net profit attributable to shareholders for the same period was 260 million yuan, up 3.3% year-on-year, with a significant increase in third-quarter performance, where revenue reached 902 million yuan, a 30.72% increase year-on-year [2] Group 2 - The company’s debt ratio stands at 27.37%, with investment income reported at 18.18 million yuan and financial expenses at -3.77 million yuan, indicating a healthy financial position [2] - The gross profit margin for Kefu Medical is reported at 53.35%, reflecting strong profitability in its operations [2] - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set by institutions is 5.456 billion yuan [2]

Investment Rating - The report maintains an "Outperform" rating for several companies in the pharmaceutical sector, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with promising pipelines and performance growth in the Biopharma/Biotech sector, maintaining an "Outperform" rating for Innovent Biologics, WuXi XDC Cayman, and others [5][23]. - It highlights the performance of the A-Shares pharmaceutical sector, which underperformed the market, with the SW Pharma & Bio index falling by 0.2% while the SHCOMP rose by 1.9% [7][18]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is currently at a normal level of 66.7% as of December 26, 2025 [13][17]. Summary by Sections 1. Continued Recommendation for Innovative Drugs and Industry Chain - The report continues to recommend innovative drugs and the associated industry chain, highlighting the high demand and potential for revaluation in the pharmaceutical sector [5][23]. - Specific companies recommended include Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical, all rated as "Outperform" [5][6]. 2. A-Shares Pharmaceutical Sector Performance - In the fourth week of December 2025, the A-Shares pharmaceutical sector underperformed the broader market, with a decline of 0.2% compared to a 1.9% increase in the SHCOMP index [7][18]. - The best-performing sub-sectors included chemical raw materials (+2.0%) and medical equipment (+0.1%), while biological products saw a slight decline of -0.1% [9][18]. 3. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 1.8% and the Hang Seng Biotechnology index down by 2.3% [18]. - In contrast, the U.S. pharmaceutical sector performed similarly to the market, with the S&P Healthcare Select Sector increasing by 1.0% [18].

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Kefu Medical (301087), indicating a slight decline in stock price and mixed capital flow on December 26, 2025 [1][2] - As of December 26, 2025, Kefu Medical's stock closed at 44.97 yuan, down 1.47%, with a turnover rate of 0.67% and a trading volume of 13,000 hands, resulting in a transaction amount of 58.5951 million yuan [1] - The capital flow data on December 26 shows a net outflow of 479.68 thousand yuan from main funds, accounting for 8.19% of the total transaction amount, while retail investors saw a net inflow of 170.81 thousand yuan, representing 2.92% of the total [1] Group 2 - Kefu Medical's Q3 2025 report reveals a total revenue of 2.398 billion yuan for the first three quarters, reflecting a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up 3.3% [2] - In Q3 2025 alone, the company achieved a revenue of 902 million yuan, marking a significant year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is up 38.68% [2] - The company maintains a debt ratio of 27.37%, with an investment income of 18.18 million yuan and a financial expense of -3.77 million yuan, alongside a gross profit margin of 53.35% [2]

Group 1 - The core viewpoint of the news is that Kefu Medical (301087) has shown positive financial performance in the third quarter of 2025, with significant year-on-year growth in revenue and net profit [2] - As of December 25, 2025, Kefu Medical's stock closed at 45.64 yuan, with a slight increase of 0.64% and a trading volume of 10,300 shares, resulting in a transaction amount of 46.99 million yuan [1] - The company reported a main revenue of 2.398 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 6.63%, and a net profit attributable to shareholders of 260 million yuan, up by 3.3% [2] Group 2 - In the third quarter of 2025, Kefu Medical achieved a single-quarter revenue of 902 million yuan, representing a year-on-year increase of 30.72%, and a net profit of approximately 92.83 million yuan, which is a 38.68% increase compared to the same period last year [2] - The company has a debt ratio of 27.37% and reported an investment income of 18.18 million yuan, with financial expenses recorded at -3.77 million yuan, indicating a strong financial position [2] - The gross profit margin for Kefu Medical stands at 53.35%, showcasing the company's efficiency in managing its production costs [2]

Core Viewpoint - The stock of Kefu Medical (301087) has shown a slight decline, with a closing price of 45.35 yuan on December 24, 2025, reflecting a decrease of 0.55% [1] Group 1: Stock Performance and Trading Data - On December 24, 2025, the stock had a turnover rate of 0.59%, with a trading volume of 11,500 hands and a transaction amount of 51.78 million yuan [1] - The net outflow of main funds was 1.98 million yuan, accounting for 3.82% of the total transaction amount, while the net inflow of speculative funds was 2.68 million yuan, making up 5.18% of the total [1] - Retail investors experienced a net outflow of 703,900 yuan, which represented 1.36% of the total transaction amount [1] Group 2: Recent Fund Flow Overview - The recent five-day fund flow data indicates fluctuations in net inflows and outflows among different investor categories [2] - On December 23, 2025, the stock price was 45.60 yuan, with a net inflow of main funds at 4.03 million yuan, while retail investors had a net outflow of 4.17 million yuan [2] - The highest net inflow of main funds in the past five days occurred on December 22, 2025, with 8.02 million yuan, while the stock price was 45.45 yuan [2] Group 3: Company Financial Metrics and Industry Comparison - Kefu Medical's total market value is 9.473 billion yuan, with a net asset value of 4.75 billion yuan and a net profit of 260 million yuan [3] - The company has a price-to-earnings ratio of 27.3 and a price-to-book ratio of 2.01, which are lower than the industry averages of 78.57 and 3.81, respectively [3] - The gross margin stands at 53.35%, and the net margin is 10.82%, both of which are above the industry averages [3] Group 4: Recent Institutional Ratings - In the last 90 days, eight institutions have provided ratings for Kefu Medical, with seven recommending a buy and one recommending an increase in holdings [4] - The average target price set by institutions over the past 90 days is 54.56 yuan [4]

Group 1 - The core viewpoint of the news is that Kefu Medical has shown a stable performance in terms of financing and stockholder metrics, indicating a solid position in the market [1][2][3] Group 2 - As of December 23, Kefu Medical's stock price increased by 0.33%, with a trading volume of 58.91 million yuan [1] - The financing buy-in amount on December 23 was 16.19 million yuan, while the financing repayment was 11.52 million yuan, resulting in a net financing buy of 4.66 million yuan [1] - The total financing and securities balance for Kefu Medical reached 121 million yuan, with the financing balance accounting for 1.26% of the circulating market value, indicating a high level compared to the past year [1] Group 3 - As of December 19, the number of shareholders for Kefu Medical was 16,000, a decrease of 5.88% from the previous period, while the average circulating shares per person increased by 6.25% to 12,140 shares [2] - For the period from January to September 2025, Kefu Medical achieved an operating income of 2.398 billion yuan, representing a year-on-year growth of 6.63%, and a net profit attributable to the parent company of 260 million yuan, up 3.30% year-on-year [2] Group 4 - Kefu Medical has distributed a total of 1.235 billion yuan in dividends since its A-share listing, with 978 million yuan distributed over the past three years [3] - As of September 30, 2025, Kefu Medical's top ten circulating shareholders saw a change, with Guotai Medical Health Stock A exiting the list [3]